X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
CM-101 is a first-in-class monoclonal antibody that neutralizes the soluble protein CCL24, which is under phase 2 clinical development for the treatment of primary sclerosing cholangitis (PSC).
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
CM-101 is a first-in-class monoclonal antibody that neutralizes the soluble protein CCL24, which is under phase 2 clinical development for the treatment of primary sclerosing cholangitis (PSC).
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2023
Details:
CM-101 is a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has potential to treat multiple severe and life-threatening inflammatory and fibrotic diseases and is currently undergoing clinical development with primary focus for the orphan diseases.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
CM-101 is a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has potential to treat multiple severe and life-threatening inflammatory and fibrotic diseases and is currently undergoing clinical development with primary focus for the orphan diseases.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
CM-101 is a first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein with pro-fibrotic and pro-inflammatory effects. It is in development for the treatment of fibro-inflammatory disorders, including primary sclerosingcholangitis and systemic sclerosis.
Lead Product(s): CM-101
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: CM-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
Details:
CM-101 is a monoclonal antibody that neutralizes the soluble protein CCL24, a cytokine family member that can trigger self-reinforcing inflammatory and fibrotic pathways implicated in a number of serious progressive diseases.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
The analysis also showed that treatment with CM-101 interfered with core PSC pathways, including inhibiting ECM-related pathways and the recruitment and presence of monocytes and macrophages.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
Details:
The findings support the role of CCL24 as a potential therapeutic target, demonstrating elevated serum levels of CCL24 in patients with dcSSc. High CCL24 serum levels were correlated with disease activity and worse prognosis as reflected.
Lead Product(s): CM-101
Therapeutic Area: Immunology Product Name: CM-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
USFDA has cleared the company's INDA for CM-101, a first-in-class monoclonal antibody targeting the soluble protein CCL24, a novel and differentiated target that is overexpressed in fibrotic tissues.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2021
Details:
The partnership will seek to provide additional insights into the mechanisms underlying CCL24-associated vascular damage and could also uncover additional application opportunities for CM-101.
Lead Product(s): CM-101
Therapeutic Area: Immunology Product Name: CM-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: ChemomAb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 27, 2021
Details:
Chemomab expects to use net proceeds from this private placement to advance in parallel three Phase 2 clinical trials for its lead product, CM-101, a novel antibody for treating rare fibrotic conditions, as well as to further develop its earlier-stage pipeline.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ChemomAb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 16, 2021
Details:
Financing will be used to advance the Chemomab pipeline. Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cormorant Asset Management
Deal Size: $45.5 million Upfront Cash: Undisclosed
Deal Type: Financing March 15, 2021
Details:
Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ChemomAb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 15, 2020
Details:
In the Phase Ib study in NAFLD patients, CM-101, a novel, first-in-class, CCL24 neutralizing antibody decreased serum biomarkers of fibrosis and inflammation with an excellent safety profile and tolerability.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
European Commission has granted Orphan Drug Designation to Chemomab's lead drug candidate CM-101 for the treatment of Primary Sclerosing Cholangitis (PSC), based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020
Details:
The clinical trial is a multicenter, double-blind, placebo-controlled study designed to evaluate the safety and efficacy profile of CM-101 in adult subjects with PSC.
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020
Details:
CM-101 composition of matter patent was issued by US, Japan and China Patent and Trademark Offices (patents 10,246,508, 10,479,830, 6553075, ZL 201580011755.4)
Lead Product(s): CM-101
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
